Educational reference only. Not medical advice. Nothing on this site is for sale.
Latest
Sign in

Cardiovascular & blood

Vesugen

Also called Vezugen, KED peptide, Lys-Glu-Asp, Везуген

Vesugen is a very short lab-made peptide (three amino acids) from Vladimir Khavinson's Russian 'peptide bioregulator' program, promoted for blood-vessel health. Its research is mostly cell and mouse studies by the group that created it. In Russia it is sold as a dietary supplement, not as a medicine.

Preclinical onlyStudied in cells or animals only. Effects in people are unknown.

All printable flashcards

Drawn from its published sequence: 3 residues, one bead each.

Overview

Vesugen is a very short lab-made peptide (three amino acids) from Vladimir Khavinson's Russian 'peptide bioregulator' program, promoted for blood-vessel health. Its research is mostly cell and mouse studies by the group that created it. In Russia it is sold as a dietary supplement, not as a medicine.

How it works

Proposed, not established. The developers propose that KED adjusts gene activity in cells. Lab studies linked it to changes in the growth of aging blood-vessel lining cells 5, higher levels of differentiation markers in aging cultured fibroblasts 4, and, in an Alzheimer's mouse model, restoration of 'mushroom'-type dendritic spines on neurons 2. None of these effects has been confirmed in controlled human studies.

What research shows

  • Mouse study (5xFAD Alzheimer's model, n=10/group, 2021): KED restored mushroom-spine numbers to normal levels but did not significantly change total spine density; its effect on synaptic plasticity was a non-significant trend 2.
  • Cell study (neurons made from skin cells of older women, 2024): KED increased dendrite branching (+32%) and total dendrite length (+42%) 3.
  • Cell study (2012): in aging human prostate fibroblast cultures it raised expression of the differentiation markers CXCL12 and WEGC1 4.
  • Cell study (2015): effects on proliferation of vascular endothelial cells during aging 5.
  • Developer reviews mention oral use in older patients with atherosclerosis and in workers in hazardous jobs, without published controlled trial data 12.
  • Most work comes from Khavinson's group; independent replication is scarce.

Doses studied in people

No verified dose from a published controlled human trial; supplement-label directions are not trial data.

Read this first: these are the amounts given to participants in published studies or written on official prescribing labels, reported for reference. They are not recommendations. Trial doses were chosen for specific patients under medical supervision, and a dose that is safe in one person can be harmful in another.

Vial math

Many research vials hold 5 or 10 mg of powder. This table shows how much ends up in each mark on a U-100 insulin syringe for common amounts of added liquid. It is arithmetic only, not a dose.

VialLiquid addedConcentrationPer unit (0.01 mL)
5 mg1 mL5 mg/mL50 mcgOpen in calculator
5 mg2 mL2.5 mg/mL25 mcgOpen in calculator
5 mg3 mL1.67 mg/mL16.7 mcgOpen in calculator
10 mg1 mL10 mg/mL100 mcgOpen in calculator
10 mg2 mL5 mg/mL50 mcgOpen in calculator
10 mg3 mL3.33 mg/mL33.3 mcgOpen in calculator

More sizes: all vial sizes · How this works: Syringes and units · Reconstitution guide.

Safety

  • No formal human safety studies have been published; long-term safety is unknown.
  • Unregulated 'research' products sold outside Russia may vary in purity and content.

Report side effects of any drug or product to the FDA through MedWatch. For a possible poisoning in the US, call Poison Control at 1-800-222-1222.

History

Developed at the St. Petersburg Institute of Bioregulation and Gerontology 1. A Russian supplement named Везуген (Vesugen), owned by the company Garmonia, holds a 2022 dietary-supplement registration 6.

Common questions

Is Vesugen a medicine?

Not in the US, where it is not FDA-approved 7. In Russia it is registered as a dietary supplement 6.

What does the evidence show?

Cell and mouse studies, including effects on nerve-cell structure in an Alzheimer's mouse model 23. No controlled human trials have been published.

Is Vesugen banned in sport?

It is not named on WADA's 2026 list, but non-approved substances generally fall under S0, prohibited at all times 8.

What are the known risks?

Human safety has not been formally studied, so risks are unknown.

Related compounds

Sources

  1. Khavinson VKh. Peptides, genome, aging. Advances in Gerontology 2014;4(4):337–345 (developer's review; Table 1 lists names, sequences and masses) Journal
  2. Khavinson V et al. Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals 2021;14(6):515 Journal
  3. Kraskovskaya N et al. Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. Int J Mol Sci 2024;25(21):11363 Journal
  4. Khavinson VKh et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med 2012;153:148–151 Journal
  5. Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation in aging. Advances in Gerontology 2015 Journal
  6. LS GEOTAR (Russian medicines reference): Везуген® (Vesugen) – dietary supplement entry, registration RU.77.99.88.003.R.002691.08.22 (12.08.2022) Regulatory
  7. FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026) Regulatory
  8. WADA 2026 Prohibited List (official English text, Dutch Treaty Series Trb. 2026, 25) Regulatory

Last reviewed 2026-10-26 · How we research · Found an error? See our corrections policy.